APOL1-Genetic Mutation and Kidney Disease Clinical Trial

Genetic Kidney Disease Research Studies

Noticing Swelling or Changes in Your Kidney Function?

APOL1-mediated kidney disease can quietly affect everyday life, often appearing as swelling in the legs or face, excess of protein in the urine, ongoing fatigue, or gradual shifts in kidney performance. Many people live with these symptoms without realizing there may be new options worth exploring. Clinical trials create an opportunity to access advanced care while helping researchers better understand this genetic condition and work toward improved treatments for the future.

At Total Research Group, our APOL1-Mediated Kidney Disease Clinical Trial is designed around patient comfort, safety, and clear communication at every step. Participants in the APOL1-Mediated Kidney Disease Clinical Trial receive attentive medical oversight, structured evaluations, and the chance to contribute to meaningful genetic kidney disease research studies that could influence tomorrow’s therapies.

Benefits of Participating

  •  Patient-first safety standards and ethical study practices
  • Modern research facilities with experienced investigators
  • Access to innovative treatment options and close health monitoring
  • Personalized medical attention from certified research professionals
  • Opportunity to support future care while receiving dedicated support throughout the study
  • Compensation may be available for time and travel

Apply for Study

This field is for validation purposes and should be left unchanged.

Explore Potential New Therapies for Kidney Diseases: Now Enrolling Participants

Participating in a clinical study can open the door to advanced care while helping shape tomorrow’s treatment options. At Total Research Group, eligible participants may receive time and travel compensation along with attentive medical supervision throughout the study journey.

Participate Today

Age

18 Years to 65 Years

Gender

All

Condition

APOL1-Mediated Kidney Disease (AMKD)

Location

Miami-Dade County, Florida

Why Is APOL1-Mediated Kidney Disease a Rising Concern — Even When Symptoms Feel Mild?

Chronic kidney disease affects more than 700 million people worldwide and can result from genetic, environmental, and existing medical conditions. One important genetic risk factor is a variation in the APOL1 gene, which has been linked to faster kidney function decline in certain populations. What makes APOL1-mediated kidney disease especially challenging is that early warning signs are often subtle or overlooked. Many individuals may only notice occasional swelling, unusual tiredness, or minor changes in urine before the condition gradually progresses. Specific genetic testing is required in order to know if you have this genetic mutation.

Because symptoms can remain quiet for long periods, awareness and early evaluation become essential for protecting long-term kidney health. Continued clinical research helps scientists better understand how this condition develops and how emerging therapies may slow or manage its impact.

Frequently Asked Questions

An APOL1-Mediated Kidney Disease Clinical Trial is a carefully supervised research study that evaluates the safety and effectiveness of investigational treatments for people at risk of genetic kidney conditions. These studies follow strict medical and ethical guidelines to protect every participant.

Adults between 18 and 65 years of age, of any gender, who have been diagnosed with APOL1-Mediated Kidney Disease (AMKD) may be eligible to participate. The study is open to individuals located in or able to visit Miami-Dade County, Florida.

Yes. Genetic Kidney Disease research studies are conducted under approved protocols, continuous medical monitoring, and patient-first safety standards. Participants are informed about potential risks and benefits before enrollment.

Participants receive close medical supervision, access to new investigational therapies, and may receive time or travel compensation. They also contribute to medical progress that may improve future kidney treatments.

You can start by submitting an interest form or contacting our team directly. After a brief pre-screening and eligibility review, qualified individuals are guided through the consent and enrollment process with full transparency and support.